Aequus Pharmaceuticals Celebrates Zimed® PF Sales Record
Company Announcements

Aequus Pharmaceuticals Celebrates Zimed® PF Sales Record

Aequus Pharmaceuticals (TSE:AQS) has released an update.

Aequus Pharmaceuticals Inc. reports a record-breaking sales quarter for Zimed® PF, the first preservative-free prostaglandin analog for glaucoma in Canada, signaling strong clinician adoption and patient benefit. As a specialty pharmaceutical company, Aequus focuses on developing and commercializing differentiated products in areas such as Ophthalmology and Optometry. Zimed® PF, approved by Health Canada in December 2022, addresses the needs of glaucoma and ocular hypertension patients, offering a preservative-free treatment option.

For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAequus Pharmaceuticals Reports Revenue Growth Amid Restructuring
TipRanks Canadian Auto-Generated NewsdeskAequus Pharmaceuticals Reports Strong Q2 Financials
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App